ArticleOncogene2006
Aspirin-triggered Lipoxin A4 inhibition of VEGF-induced endothelial cell migration involves actin polymerization and focal adhesion assembly.
Article in Oncogene, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 83 citations in OpenAlex.
- G protein-coupled receptors and inflammation resolution signaling networks in the heart: Pharmacology and potential for innovative therapeutics.Pharmacological reviews · 2026Review
- Aspirin-triggered DHA metabolites inhibit angiogenesis.Frontiers in pharmacology · 2025Article
- Improving hard metal implant and soft tissue integration by modulating the "inflammatory-fibrous complex" response.Bioactive materials · 2023Article
- Immunomodulation of periodontitis with SPMs.Frontiers in oral health · 2023Review
- The Impact of Resolution of Inflammation on Tumor Microenvironment: Exploring New Ways to Control Cancer Progression.Cancers · 2022Review
- Wear Resistance and Biocompatibility of Co-Cr Dental Alloys Fabricated with CAST and SLM Techniques.Materials (Basel, Switzerland) · 2022Article
- Specialized Pro-Resolving Lipid Mediators: New Therapeutic Approaches for Vascular Remodeling.International journal of molecular sciences · 2022Review
- Safranal Inhibits AngiogenesisFrontiers in oncology · 2021Article
- 6'-Sialylgalactose inhibits vascular endothelial growth factor receptor 2-mediated angiogenesis.Experimental & molecular medicine · 2019Article
- Specialized Proresolving Mediators in Innate and Adaptive Immune Responses in Airway Diseases.Physiological reviews · 2018Review
- Overexpression of preeclampsia induced microRNA-26a-5p leads to proteinuria in zebrafish.Scientific reports · 2018Article
- Lipid mediators in the regulation of endothelial barriers.Tissue barriers · 2018Review
- Coenzyme Q10 Prevents Senescence and Dysfunction Caused by Oxidative Stress in Vascular Endothelial Cells.Oxidative medicine and cellular longevity · 2018Article
- Specialized pro-resolving mediators: endogenous regulators of infection and inflammation.Nature reviews. Immunology · 2016Review
- Requirement of novel amino acid fragments of orphan nuclear receptor TR3/Nur77 for its functions in angiogenesis.Oncotarget · 2015Article
- Albumin infusion for the critically ill--is it beneficial and, if so, why and how?Critical care (London, England) · 2015Article
- Innate immunity is a key factor for the resolution of inflammation in asthma.European respiratory review : an official journal of the European Respiratory Society · 2015Review
- Gold nanoparticles inhibit VEGF165-induced migration and tube formation of endothelial cells via the Akt pathway.BioMed research international · 2014Article
- A novel function of p38-regulated/activated kinase in endothelial cell migration and tumor angiogenesis.Molecular and cellular biology · 2012Article
- Cyclooxygenases and lipoxygenases in cancer.Cancer metastasis reviews · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Angiogenesis, the growth of new capillaries from pre-existing ones, occurs through dynamic functions of the endothelial cells (EC), including migration, which is essential to achieve an organized formation of the vessel sprout. We demonstrated previously that an aspirin-triggered lipoxin analog, 15-epi-16-(para-fluoro)-phenoxy-lipoxin A4 (ATL-1), inhibits vascular endothelial growth factor (VEGF)-induced EC migration. In the present study, we investigated the effects of ATL-1 in the actin cytoskeleton reorganization of EC stimulated with VEGF. Pretreatment of EC with ATL-1 caused a reduction in VEGF-induced stress fibers and therefore reduced the intracellular content of filamentous actin. A concomitant impairment in stress-activated protein kinase (SAPK2/p38) phosphorylation suggests that ATL inhibition of VEGF-stimulated actin polymerization involves the SAPK2/p38 pathway. Moreover, ATL-1 treatment inhibited focal adhesion clustering due to inhibition of focal adhesion kinase (FAK) phosphorylation and the subsequent association of FAK with the actin cytoskeleton. This final event, which ultimately allows cell migration, was reverted by an LX receptor antagonist, but not by a cys-LT1R antagonist, indicating an effect via the G-protein-linked LXA4 receptor. Together our results provide evidence that ATL-1 inhibits EC migration via the concerted inhibition of actin polymerization and proper assembly of focal adhesions, supporting a role for these novel lipid mediators as angiogenesis modulators.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.